Author name: DrugPatentWatch

The generic pharmaceutical industry has spent thirty years perfecting a business model that no longer works. The playbook was elegant […]

A deep-dive strategic guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on the regulatory, patent, and

Who this is for: IP teams at innovator and generic companies, portfolio managers running LOE models, R&D leads evaluating lifecycle

The Market You’re Actually Competing In The generic drug industry saves the U.S. healthcare system more than $445 billion per

Who This Guide Is For This is not an overview. It is a field manual for IP counsel preparing a

Introduction: Two Systems Built for Different Problems, Forced to Coexist In pharmaceutical patent law, the rules changed permanently on September

The question sounds deceptively simple: should you put a brand name on your generic drug? In practice, it is one

The conventional view of a pharmaceutical patent is simple: it is a monopoly right, a wall built to keep competitors

The pharmaceutical industry has spent much of the past decade performing a kind of collective memory erasure about small molecules.